Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Immuneering presented oral data at ASCO showing atebimetinib plus chemotherapy achieved a median overall survival of 17.3 months in 55 first-line pancreatic cancer patients, compared to 8.5 months for standard of care. The regimen demonstrated a favorable safety profile with only two categories of Grade 3+ treatment-related adverse events occurring in ≥10% of patients, both chemotherapy-related, and no Grade 4 or 5 atebimetinib-related events. 84% of participants maintained or gained weight at three months, supporting preserved functional status.
Key figures
- Drug Name
- atebimetinib
- Phase Of Trial
- Phase 2a
- Patient count
- 55
- Median os months
- 17.3
- Median pfs months
- 8.3
- Disease control rate
- 82%
- Median os soc months
- 8.5
- Overall response rate
- 36%
- Weight stability rate
- 84%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.